Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRAS Q61R or KRAS Q61R Mutation in Colorectal Carcinoma

11 Feb 2016

Abstract excerpt

Anti-epidermal growth factor receptor-targeted therapy is only indicated in RAS wild-type colorectal carcinomas (CRCs). It is recommended that both NRAS and KRAS mutation testing to be performed before a CRC is considered RAS wild-type. Given that mutation-specific immunohistochemistry (IHC) has been shown to be sensitive and specific for the detection of NRAS mutations in melanoma, we assessed the specificity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to HER2/EGFR in Cancer Research
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26862952
DOI: 10.1097/pai.0000000000000333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRAS Q61R or KRAS Q61R Mutation in Colorectal CarcinomaPMID 26862952Read ↗

NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer.Semantic proximity Read ↗

Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.Semantic proximity Read ↗

SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.Semantic proximity Read ↗

Immunohistochemical Detection of NRASQ61R Mutation in Diverse Tumor Types.Semantic proximity Read ↗

Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.Semantic proximity Read ↗

Mutation‐specific antibody detects mutant BRAF<sup>V600E</sup> protein expression in human colon carcinomasSemantic proximity Read ↗

NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2Semantic proximity Read ↗

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.Semantic proximity Read ↗

Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.